

Plaque Psoriasis Market Projected to Grow with Biologic Therapies

Plaque psoriasis is a chronic autoimmune skin disorder characterized by red, inflamed patches covered with silvery scales. Therapeutic products for plaque psoriasis include topical corticosteroids, vitamin D analogues, systemic agents, and the latest biologic therapies such as IL-17 and IL-23 inhibitors. Biologic treatments offer targeted modulation of the immune response, minimizing systemic side effects and delivering faster, more durable clearance of psoriatic lesions.

The adoption of self-injectable pens and prefilled syringes enhances patient convenience, adherence, and overall treatment satisfaction. Rising patient awareness, improvements in diagnostic methods, and robust clinical trial data have collectively expanded the [Plaque Psoriasis Market](#) treatment landscape. Furthermore, healthcare providers are increasingly leveraging market research and real-world evidence to optimize treatment algorithms, reduce hospital visits, and improve long-term patient outcomes. The integration of teledermatology platforms has also played a crucial role in remote patient monitoring and timely intervention.

The plaque psoriasis market is estimated to be valued at USD 32.28 Bn in 2025 and is expected to reach USD 52.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032.

Key Takeaways

Key players operating in the Plaque Psoriasis Market are AbbVie Inc., Novartis International AG, Johnson & Johnson (Janssen Pharmaceuticals), Eli Lilly and Company, and Amgen Inc. With growing unmet needs, the market opportunities lie in expanding access to advanced biological treatments in emerging economies. Increased healthcare spending, favorable reimbursement policies, and government initiatives to improve dermatological care are opening new market segments. Additionally, strategic collaborations between pharmaceutical companies and research institutes are expected to drive innovation in next-generation biologics and small molecule inhibitors. Market analysis indicates that combination therapies and personalized medicine approaches hold significant promise for addressing moderate to severe cases, thereby broadening the market size and driving sustainable market growth. The rapid proliferation of biologic therapies represents a key technological

